$GILD paid $4.9B for $FTSV even though their combo trials are w/ $BMY, $MRK, &amp; other BP's PD-1 drugs. GILD since  got zimberelimab from $RCUS. Thinking of $TRIL CRs/PRs plus CEO solid tumor comments &amp; seeing GILD pipeline on solid tumor makes you think.🧐 https://t.co/21OsS8cQwZ